THERAPANACEA

Their core work

TheraPanacea is a Paris-based medical AI company developing software that applies deep learning and reinforcement learning to cancer radiotherapy planning. Their technology helps radiation oncologists deliver more precise, adaptive dose treatments — particularly for MRI-guided radiotherapy — by automating tasks like deformable image registration, treatment planning, and cumulative dose estimation. In practice, they sit between linear accelerator hardware and clinical workflows, turning imaging data into faster, safer, personalized treatment decisions. Both of their H2020 projects were led by them, which signals a product company building proprietary technology rather than a research lab.

What they specialise in

How they've shifted over time

The 2017 ERC-POC project focused on the algorithmic foundations — deep learning, deformable registration, and cumulative dose estimation for adaptive radiotherapy. By 2019, with the ART-AI SME grant, the work shifted toward productization: MRI-guided dosimetry on actual linear accelerators, with reinforcement learning layered on top. The trajectory is a clean research-to-product arc, moving from proof-of-concept algorithms to a clinical software tool aimed at real treatment workflows.

They are moving from algorithm development toward deployable clinical AI software for MRI-linac systems, which makes them a strong partner for anyone building around modern image-guided radiotherapy hardware.

How they like to work

TheraPanacea coordinated both of its H2020 projects, which is typical of a focused SME building its own product rather than joining large research consortia. The dataset shows no recorded consortium partners in these two grants, suggesting either very small teams or that their collaborators sit outside the H2020 participation records visible here. They behave like a product-led company that uses EU funding to de-risk its own development pipeline.

The available H2020 data shows no linked consortium partners for either project, so their collaboration network cannot be mapped from this dataset alone. Their geographic footprint in H2020 is anchored in Paris, France.

What sets them apart

TheraPanacea is a rare example of an SME that won both an ERC Proof-of-Concept grant and an SME Instrument grant back-to-back in the same narrow domain — AI for radiotherapy. That combination signals both scientific credibility and commercial ambition, which is unusual for a small company. For a partner, this means they bring deployable software rather than academic prototypes, and they specifically know the MRI-linac treatment planning space.

Highlights from their portfolio

• ART-AI
  Large EUR 2.48M SME Instrument grant focused on bringing AI-powered adaptive dosimetry for MRI-guided radiotherapy into clinical use.
• TheraPanacea
  ERC Proof-of-Concept grant that validated the scientific core — deep learning for adaptive, personalized radiotherapy — before the company scaled up with ART-AI.